Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers

Autor: Evangelos Terpos, Ioannis P. Trougakos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Sentiljana Gumeni, Filia Apostolakou, Aimilia D. Sklirou, Maria Gavriatopoulou, Stamatia Skourti, Efstathios Kastritis, Eleni Korompoki, Ioannis Papassotiriou, Meletios A. Dimopoulos
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Cells, Vol 10, Iss 8, p 1942 (2021)
Druh dokumentu: article
ISSN: 2073-4409
DOI: 10.3390/cells10081942
Popis: The aim of this study was to investigate the kinetics of neutralizing antibodies (NAbs) and anti-SARS-CoV-2 anti-S-RBD IgGs up to three months after the second vaccination dose with the BNT162b2 mRNA vaccine. NAbs and anti-S-RBD levels were measured on days 1 (before the first vaccine shot), 8, 22 (before the second shot), 36, 50, and three months after the second vaccination (D111) (NCT04743388). 283 health workers were included in this study. NAbs showed a rapid increase from D8 to D36 at a constant rate of about 3% per day and reached a median (SD) of 97.2% (4.7) at D36. From D36 to D50, a slight decrease in NAbs values was detected and it became more prominent between D50 and D111 when the rate of decline was determined at −0.11 per day. The median (SD) NAbs value at D111 was 92.7% (11.8). A similar pattern was also observed for anti-S-RBD antibodies. Anti-S-RBDs showed a steeper increase during D22–D36 and a lower decline rate during D36–D111. Prior COVID-19 infection and younger age were associated with superior antibody responses over time. In conclusion, we found a persistent but declining anti-SARS-CoV-2 humoral immunity at 3 months following full vaccination with BNT162b2 in healthy individuals.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje